Paul J Hesketh


Ontology type: schema:Person     


Person Info

NAME

Paul J

SURNAME

Hesketh

Publications in SciGraph latest 50 shown

  • 2018-04 Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic in SUPPORTIVE CARE IN CANCER
  • 2017-01 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2017-01 Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2017-01 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents in SUPPORTIVE CARE IN CANCER
  • 2017-01 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2016-05 Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis in SUPPORTIVE CARE IN CANCER
  • 2016-04 Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies in SUPPORTIVE CARE IN CANCER
  • 2012-10 Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC) in SUPPORTIVE CARE IN CANCER
  • 2012-07 Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study in SUPPORTIVE CARE IN CANCER
  • 2012-05 Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2012-03 Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting in SUPPORTIVE CARE IN CANCER
  • 2011-12 Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2011-09 Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC) in SUPPORTIVE CARE IN CANCER
  • 2011-03 Acute emesis: moderately emetogenic chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2011-03 Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art in SUPPORTIVE CARE IN CANCER
  • 2011-03 Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2010-09 Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2009-08 Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide in SUPPORTIVE CARE IN CANCER
  • 2008-09 Birth and re-birth in SUPPORTIVE CARE IN CANCER
  • 2007-08 Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study in INVESTIGATIONAL NEW DRUGS
  • 2006-04 Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response in SUPPORTIVE CARE IN CANCER
  • 2005-07 Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2005-04 Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2005-02 Acute emesis: moderately emetogenic chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2005-02 Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update in SUPPORTIVE CARE IN CANCER
  • 2005-02 Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy in SUPPORTIVE CARE IN CANCER
  • 2005-01 The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in AMERICAN JOURNAL OF CANCER
  • 2004-08 Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches in SUPPORTIVE CARE IN CANCER
  • 2003 Chemotherapy-Induced Nausea and Vomiting in ONCOLOGIC THERAPIES
  • 2002-10 Antiemetic guidelines: creating a more practical treatment approach in SUPPORTIVE CARE IN CANCER
  • 2001-12 Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support in BONE MARROW TRANSPLANTATION
  • 2001-07 Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting in SUPPORTIVE CARE IN CANCER
  • 2000-01 Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen in SUPPORTIVE CARE IN CANCER
  • 1999-10 Antiemetics for Cancer Chemotherapy—Induced Nausea and Vomiting in DRUGS IN R&D
  • 1999 Chemotherapy-Induced Nausea and Vomiting in ONCOLOGIC THERAPIES
  • 1998-08 Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting in SUPPORTIVE CARE IN CANCER
  • 1998-04 Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity in SUPPORTIVE CARE IN CANCER
  • 1998 Methodology of Antiemetic Trials: Response Assessment, Evaluation of New Agents, and Definition of Chemotherapy Emetogenicity in PERUGIA CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY
  • 1997-07 Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions in SUPPORTIVE CARE IN CANCER
  • 1996-11 Drug Treatment of Chemotherapy-Induced Delayed Emesis in DRUGS
  • 1996-03 Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide in SUPPORTIVE CARE IN CANCER
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.415731.5", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.429997.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239424.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411900.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.427738.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.27860.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.213910.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26009.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.21729.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.189504.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240845.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.59062.38", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.475010.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.67033.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415224.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.468189.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417993.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419182.7", 
            "type": "Organization"
          }
        ], 
        "familyName": "Hesketh", 
        "givenName": "Paul J", 
        "id": "sg:person.0665424330.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665424330.55"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_911.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0665424330.55'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0665424330.55'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0665424330.55'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0665424330.55'


     

    This table displays all metadata directly associated to this object as RDF triples.

    54 TRIPLES      10 PREDICATES      30 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0665424330.55 schema:affiliation N2ea64e2eb5b749e7b3cdc4260553d6ec
    2 https://www.grid.ac/institutes/grid.189504.1
    3 https://www.grid.ac/institutes/grid.213910.8
    4 https://www.grid.ac/institutes/grid.21729.3f
    5 https://www.grid.ac/institutes/grid.239424.a
    6 https://www.grid.ac/institutes/grid.240845.f
    7 https://www.grid.ac/institutes/grid.26009.3d
    8 https://www.grid.ac/institutes/grid.27860.3b
    9 https://www.grid.ac/institutes/grid.411900.d
    10 https://www.grid.ac/institutes/grid.415224.4
    11 https://www.grid.ac/institutes/grid.417993.1
    12 https://www.grid.ac/institutes/grid.419182.7
    13 https://www.grid.ac/institutes/grid.427738.d
    14 https://www.grid.ac/institutes/grid.429997.8
    15 https://www.grid.ac/institutes/grid.468189.a
    16 https://www.grid.ac/institutes/grid.475010.7
    17 https://www.grid.ac/institutes/grid.51462.34
    18 https://www.grid.ac/institutes/grid.59062.38
    19 https://www.grid.ac/institutes/grid.67033.31
    20 https://www.grid.ac/institutes/grid.7700.0
    21 schema:familyName Hesketh
    22 schema:givenName Paul J
    23 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665424330.55
    24 schema:sdDatePublished 2019-03-07T15:14
    25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    26 schema:sdPublisher N9d7f95e7de57477391964a3c1a7f8d15
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset persons
    29 rdf:type schema:Person
    30 N2ea64e2eb5b749e7b3cdc4260553d6ec schema:affiliation https://www.grid.ac/institutes/grid.415731.5
    31 sgo:isCurrent true
    32 rdf:type schema:OrganizationRole
    33 N9d7f95e7de57477391964a3c1a7f8d15 schema:name Springer Nature - SN SciGraph project
    34 rdf:type schema:Organization
    35 https://www.grid.ac/institutes/grid.189504.1 schema:Organization
    36 https://www.grid.ac/institutes/grid.213910.8 schema:Organization
    37 https://www.grid.ac/institutes/grid.21729.3f schema:Organization
    38 https://www.grid.ac/institutes/grid.239424.a schema:Organization
    39 https://www.grid.ac/institutes/grid.240845.f schema:Organization
    40 https://www.grid.ac/institutes/grid.26009.3d schema:Organization
    41 https://www.grid.ac/institutes/grid.27860.3b schema:Organization
    42 https://www.grid.ac/institutes/grid.411900.d schema:Organization
    43 https://www.grid.ac/institutes/grid.415224.4 schema:Organization
    44 https://www.grid.ac/institutes/grid.415731.5 schema:Organization
    45 https://www.grid.ac/institutes/grid.417993.1 schema:Organization
    46 https://www.grid.ac/institutes/grid.419182.7 schema:Organization
    47 https://www.grid.ac/institutes/grid.427738.d schema:Organization
    48 https://www.grid.ac/institutes/grid.429997.8 schema:Organization
    49 https://www.grid.ac/institutes/grid.468189.a schema:Organization
    50 https://www.grid.ac/institutes/grid.475010.7 schema:Organization
    51 https://www.grid.ac/institutes/grid.51462.34 schema:Organization
    52 https://www.grid.ac/institutes/grid.59062.38 schema:Organization
    53 https://www.grid.ac/institutes/grid.67033.31 schema:Organization
    54 https://www.grid.ac/institutes/grid.7700.0 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...